A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping

被引:31
|
作者
Gardner, Thomas W. [1 ]
Sundstrom, Jeffrey M. [2 ]
机构
[1] Univ Michigan, Med Sch, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA
[2] Penn State Coll Med, Penn State Hershey Eye Ctr, 500 Univ Dr,HU19, Hershey, PA 17033 USA
关键词
Diabetic retinopathy; Vitreous proteomics; Neurovascular unit; Retinal failure; Molecular diagnosis; BREAST-CANCER; VISUAL-ACUITY; NEURODEGENERATION; DISORGANIZATION; EXPRESSION; CYTOKINE; PROTEIN; RETINA; MARKER; HEALTH;
D O I
10.1016/j.visres.2017.03.006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This paper presents a new approach to the prevention and treatment of early stage diabetic retinopathy before vision is severely impaired. This approach includes two major steps. The first step is to understand the mechanisms of vision impairment and classify diabetic retinopathy on the basis of pathophysiologic adaptations, rather than on the presence of advanced pathologic lesions, as defined by current clinical practice conventions. The second step is to develop patient-specific molecular diagnoses of diabetic retinopathy so that patients can be treated based on their individual characteristics, a process analogous to the individualized diagnosis and treatment of cancer patients. This step is illustrated by proteomic analysis of vitreous fluid that reveals evidence of neuroretinal degeneration and inflammation, as well as vascular proliferation. Together, these steps may lead to improved means to preserve vision in the ever-increasing number of patients with diabetes worldwide. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:153 / 160
页数:8
相关论文
共 50 条
  • [21] MOSAICS VERSUS EARLY TREATMENT DIABETIC RETINOPATHY SEVEN STANDARD FIELDS FOR EVALUATION OF DIABETIC RETINOPATHY SEVERITY
    Li, Helen K.
    Esquivel, Adol
    Hubbard, Larry D.
    Florez-Arango, Jose F.
    Danis, Ronald P.
    Krupinski, Elizabeth A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (08): : 1553 - 1563
  • [22] Analysis of the Clinical Efficacy of Minocycline in the Treatment of Diabetic Retinopathy
    Song, Lina
    Rong, Yunjiu
    Tang, K.
    Song, Xueling
    Li, Z.
    Li, Xuan
    Yu, Leilei
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 83 : 231 - 235
  • [23] Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?
    Perco, Paul
    Mayer, Gert
    KIDNEY INTERNATIONAL, 2018, 93 (02) : 308 - 310
  • [24] Genetic insights and emerging therapeutics in diabetic retinopathy: from molecular pathways to personalized medicine
    Pei, Xiaoting
    Huang, Duliurui
    Li, Zhijie
    FRONTIERS IN GENETICS, 2024, 15
  • [25] Evidence-Based Treatment of Diabetic Retinopathy
    El Rami, Hala
    Barham, Rasha
    Sun, Jennifer K.
    Silva, Paolo S.
    SEMINARS IN OPHTHALMOLOGY, 2017, 32 (01) : 67 - 74
  • [26] Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects
    Saxena, Rohit
    Singh, Digvijay
    Saklani, Ravi
    Gupta, Suresh Kumar
    EYE AND BRAIN, 2016, 8 : 1 - 13
  • [27] Diabetic Retinopathy: Early Diagnosis and Effective Treatment Potentially Dangerous treatment
    Egidi, Guenther
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2010, 107 (25): : 444 - 444
  • [28] Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26
    Cusick, M
    Chew, EY
    Hoogwerf, B
    Agrón, E
    Wu, L
    Lindley, A
    Ferris, FL
    KIDNEY INTERNATIONAL, 2004, 66 (03) : 1173 - 1179
  • [29] The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy
    Sun, Jennifer K.
    Jampol, Lee M.
    OPHTHALMIC RESEARCH, 2019, 62 (04) : 225 - 230